NEW YORK (GenomeWeb) – Pacific Biosciences raised $20.6 million in net proceeds through the sale of 3 million shares of its common stock during the first half of 2014, the company disclosed in its Form 10-Q filed with the US Securities and Exchange Commission on Monday.

PacBio said it sold the stock at an average price of $7.12 per share in an at-the-market offering, a type of offering in which shares are offered at the prevailing market prices. The firm added that its current at-the-market offering program has about $17.9 million of common shares available for future sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.